CpG 1018 Is an Effective Adjuvant for Influenza Nucleoprotein

Area of Science:

• Immunology
• Vaccinology
• Virology

Background:

• Current influenza vaccines target variable hemagglutinin, necessitating annual updates.
• Intracellular influenza nucleoprotein (NP) is conserved and a target for universal T cell vaccines.
• NP-induced vaccines require enhanced cytotoxic T lymphocyte (CTL) responses for efficacy.

Purpose of the Study:

• To compare the adjuvant effects of CpG 1018 and AddaVax on recombinant NP-induced CTL responses and protection.
• To evaluate CpG 1018 for intradermal NP immunization and AddaVax for intramuscular NP immunization in murine models.

Main Methods:

• Murine models were immunized with recombinant NP using CpG 1018 (intradermal) or AddaVax (intramuscular).
• Humoral and cellular immune responses, including antibody titers and T cell cytokine production (IFNγ, IL4), were analyzed.
• Vaccine efficacy was assessed by protection against lethal influenza viral challenge.

Main Results:

• CpG 1018 significantly enhanced NP-induced humoral and cellular immunity compared to AddaVax.
• CpG 1018 promoted Th1-biased responses, while AddaVax induced balanced Th1/Th2 responses.
• CpG 1018 immunization conferred significant protection against lethal viral challenge, unlike AddaVax.

Conclusions:

• CpG 1018 is a potent adjuvant for enhancing influenza NP-specific CTL responses.
• CpG 1018 demonstrates superior efficacy in inducing protective immunity against influenza compared to AddaVax.
• CpG 1018 is a promising adjuvant for developing universal influenza T cell vaccines targeting NP.